Zepbound: What It Is, How It Works, and How It Compares to Wegovy, Ozempic, and Saxenda

What Is Zepbound and How Does It Differ from Other GLP-1 Drugs?

Zepbound is tirzepatide formulated and FDA-approved specifically for chronic weight management. It is the only approved obesity drug that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously. All other drugs in this space, including Wegovy (semaglutide 2.4 mg), Ozempic (semaglutide 1 mg), and Saxenda (liraglutide 3 mg), activate only the GLP-1 receptor.

That second mechanism matters clinically. GIP receptors are expressed in adipose tissue, and preclinical data suggest GIP agonism may enhance fat mobilization beyond what GLP-1 agonism alone provides. The net effect, seen across the SURMOUNT program, is a weight-loss magnitude that consistently exceeds GLP-1 mono-agonists in head-to-comparable-dose analyses [1][2].

Mounjaro is the same molecule, tirzepatide, but it carries a separate FDA approval for type 2 diabetes management rather than obesity. Prescribers sometimes use Mounjaro off-label for weight loss when Zepbound is unavailable, though formulary coverage differs substantially between the two brand names.

The SURMOUNT Trial Program: What the Data Actually Show

The SURMOUNT program is the four-trial series that generated Zepbound's approval and post-marketing evidence base. Each trial answers a different clinical question.

SURMOUNT-1 (N=2,539 to 72 weeks) enrolled adults with obesity or overweight plus at least one comorbidity, excluding type 2 diabetes. Participants randomized to tirzepatide 5 mg, 10 mg, and 15 mg lost a mean of 15.0%, 19.5%, and 20.9% of body weight, respectively, versus 3.1% with placebo [1]. At 15 mg, 36.2% of participants achieved weight loss of 25% or more, a threshold rarely seen with any pharmacotherapy. The trial was published in the New England Journal of Medicine in 2022.

SURMOUNT-2 (N=938 to 72 weeks) tested tirzepatide specifically in adults with type 2 diabetes and obesity. Mean weight loss was 12.8% (10 mg) and 14.7% (15 mg) versus 3.2% placebo [2]. Weight loss was attenuated compared to SURMOUNT-1, consistent with the pattern seen with semaglutide between STEP-1 and STEP-2.

SURMOUNT-3 (N=579) preceded tirzepatide with a 12-week intensive lifestyle lead-in. Participants who then randomized to tirzepatide 15 mg achieved an additional 18.4% weight loss from the post-lifestyle baseline, for a total mean weight reduction of 26.6% from their original starting weight [3]. That figure approaches outcomes seen in bariatric surgery cohorts.

SURMOUNT-4 (N=670, JAMA 2024) is the maintenance trial. After 36 weeks of open-label tirzepatide titrated to 15 mg, participants were re-randomized to continue the drug or switch to placebo for another 52 weeks. Those who continued lost an additional 5.5% of weight; those switched to placebo regained 14.8% [4]. The regain data confirm that tirzepatide, like semaglutide, requires ongoing use to sustain results.

How Zepbound Compares to Wegovy (Semaglutide 2.4 mg)

No randomized head-to-head trial has directly compared Zepbound to Wegovy in a weight-management population at this writing. The comparison currently rests on cross-trial data with similar eligibility criteria.

STEP-1 (N=1,961 to 68 weeks) is the key trial for Wegovy. Participants with obesity or overweight plus comorbidities lost a mean of 14.9% of body weight on semaglutide 2.4 mg versus 2.4% on placebo [5]. At 68 weeks, 86.4% of semaglutide participants had lost at least 5% of body weight.

Across SURMOUNT-1 (72 weeks) versus STEP-1 (68 weeks), tirzepatide 15 mg produced roughly 6 percentage points more weight loss. Absolute differences of this magnitude are clinically significant: a 90-kg patient loses approximately 18.8 kg on tirzepatide 15 mg versus 13.4 kg on semaglutide 2.4 mg under trial conditions. The populations are not identical, and confounding exists, but the gap is consistent across dose-escalation analyses.

The HealthRX clinical team uses this cross-trial comparison framework for shared decision-making with patients who qualify for either agent:

| Parameter | Zepbound (tirzepatide 15 mg) | Wegovy (semaglutide 2.4 mg) | |---|---|---| | Trial (weeks) | SURMOUNT-1 (72 wk) | STEP-1 (68 wk) | | Mean weight loss | 20.9% | 14.9% | | ≥5% responder rate | 91% | 86.4% | | ≥20% responder rate | 56.8% | 32.0% | | Injection frequency | Once weekly | Once weekly | | CV outcomes trial | Ongoing (SURPASS-CVOT) | SELECT (20.6% MACE reduction) | | FDA obesity approval | Nov 2023 | June 2021 |

Wegovy has one cardiovascular advantage that Zepbound currently cannot match in published data. The SELECT trial (N=17,604, median 39.8 months) found that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% versus placebo in adults with established cardiovascular disease and obesity but without diabetes [6]. The FDA updated Wegovy's label in March 2024 to include this cardiovascular risk-reduction indication. Zepbound's parallel cardiovascular trial is ongoing.

How Zepbound Compares to Ozempic (Semaglutide 1 mg)

Ozempic is FDA-approved for type 2 diabetes management and cardiovascular risk reduction, not for obesity. Its approved dose is 0.5 mg to 2 mg once weekly. Because the weight-management dose of semaglutide (2.4 mg in Wegovy) exceeds the standard diabetes dose, direct comparisons between Zepbound and Ozempic are complicated by dose inequivalence.

STEP-2 (N=1,210 to 68 weeks, The Lancet 2021) tested semaglutide 1 mg in adults with type 2 diabetes and obesity. Mean weight loss was 9.6% versus 3.4% placebo [7]. Zepbound in SURMOUNT-2, a comparable diabetes population, produced 14.7% at 15 mg [2]. That is a 5.1 percentage-point difference favoring tirzepatide, even at the diabetes-focused semaglutide dose.

Prescribers and patients sometimes encounter Ozempic in weight-loss discussions because its widespread availability during Wegovy shortages led to off-label use. The FDA does not approve Ozempic for obesity, and its label does not include weight-management dosing guidance. Ozempic's injector pen is also calibrated for lower doses, which creates practical barriers to off-label titration up to 2.4 mg.

How Zepbound Compares to Saxenda (Liraglutide 3 mg)

Saxenda (liraglutide 3 mg) is the oldest approved weight-management injectable in this class, approved by the FDA in December 2014. Unlike Zepbound and Wegovy, Saxenda requires a daily subcutaneous injection, a meaningful adherence barrier for many patients.

STEP-8 (N=338 to 68 weeks, JAMA 2022) is the only published randomized head-to-head trial comparing semaglutide 2.4 mg to liraglutide 3 mg directly. Semaglutide produced 15.8% mean weight loss versus 6.4% with liraglutide, a difference of 9.4 percentage points [8]. Discontinuation due to adverse events was similar between groups (3.5% semaglutide vs. 7.8% liraglutide).

No published RCT has directly compared tirzepatide to liraglutide in a weight-management population. Extrapolating from SURMOUNT-1 versus STEP-8 trial-level data places tirzepatide 15 mg roughly 14 percentage points above liraglutide 3 mg in mean weight loss. Saxenda is generally considered a second-line option behind both Wegovy and Zepbound when cost or access is not the limiting factor.

The once-daily injection schedule for Saxenda is worth noting for patients who prefer a more controlled titration pace or who have prior experience with daily injectable regimens such as insulin. The AACE/ACE obesity clinical practice guidelines note that individualized treatment selection should account for comorbidity profile, tolerability, and patient preference alongside efficacy data [9].

Zepbound Dosing and Titration Schedule

The FDA-approved starting dose is 2.5 mg subcutaneously once weekly for four weeks. The dose escalates by 2.5 mg every four weeks until the patient reaches either their maintenance dose or the maximum approved dose of 15 mg. The full escalation schedule is:

• Weeks 1 through 4: 2.5 mg once weekly
• Weeks 5 through 8: 5 mg once weekly
• Weeks 9 through 12: 7.5 mg once weekly
• Weeks 13 through 16: 10 mg once weekly
• Weeks 17 through 20: 12.5 mg once weekly
• Week 21 onward: 15 mg once weekly (or remain at a tolerated lower maintenance dose)

The Zepbound FDA label specifies that if the 15 mg dose is not tolerated, patients may remain on 10 mg as a maintenance dose [10]. Titration can be slowed beyond the four-week intervals at physician discretion for patients with persistent gastrointestinal side effects.

Zepbound is injected subcutaneously in the abdomen, upper arm, or thigh. Injection sites should be rotated. Unlike oral semaglutide (Rybelsus), Zepbound has no food-timing requirements.

Side Effects and Safety Profile

The most frequently reported adverse events in the SURMOUNT trials were gastrointestinal: nausea (32.7% at 15 mg vs. 9.3% placebo in SURMOUNT-1), diarrhea (22.7% vs. 11.9%), vomiting (16.1% vs. 4.1%), and constipation (16.7% vs. 10.5%) [1]. The majority of these events were mild to moderate and concentrated during dose escalation. They tended to resolve after reaching a stable maintenance dose.

Discontinuation due to adverse events in SURMOUNT-1 was 7.4% for tirzepatide (pooled doses) versus 2.3% for placebo [1]. That rate compares favorably to liraglutide, which showed a 7.8% discontinuation rate due to adverse events in STEP-8 [8].

The Zepbound FDA label carries a boxed warning for thyroid C-cell tumors, derived from rodent studies showing dose-dependent thyroid carcinomas with GLP-1 receptor agonists. Human relevance is not established, but tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [10]. Patients should also be monitored for acute pancreatitis, cholelithiasis, acute kidney injury from dehydration, and diabetic retinopathy complications if the drug is used in the context of type 2 diabetes.

Heart rate increase of approximately 2 to 4 beats per minute has been observed with tirzepatide, consistent with the class effect seen with GLP-1 receptor agonists.

Zepbound and Birth Control Pills

A clinically relevant drug interaction concerns oral contraceptives. Tirzepatide slows gastric emptying, which may reduce the absorption rate of orally administered medications during the first several weeks of treatment or during dose escalation. The Zepbound FDA label advises that patients using oral contraceptives switch to a non-oral contraceptive method, or add a barrier method, for four weeks after initiating Zepbound and for four weeks after each dose escalation [10]. After gastric motility stabilizes at a maintenance dose, this precaution is no longer required. Patients using injectable, implantable, or intrauterine contraceptives are not affected by this interaction.

Who Qualifies for Zepbound

The FDA indication covers adults with:

• A BMI ≥30 kg/m², or
• A BMI ≥27 kg/m² plus at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease)

Zepbound is indicated as an adjunct to a reduced-calorie diet and increased physical activity. Prescribers should document at least one failed attempt at lifestyle modification before initiating pharmacotherapy per most insurer prior authorization requirements.

The AACE/ACE 2016 guidelines state: "When pharmacotherapy is chosen, medications should be prescribed only within their approved indications and within a comprehensive program that includes dietary therapy, physical activity, and behavioral intervention." [9]

Zepbound is not approved for use in pediatric patients or during pregnancy. Its safety in patients with a history of pancreatitis has not been established.

Zepbound vs. Mounjaro: Same Drug, Different Indication

Mounjaro and Zepbound contain identical active ingredients at identical doses. The distinction is regulatory. Mounjaro received FDA approval in May 2022 for type 2 diabetes management. Zepbound received a separate FDA approval in November 2023 for chronic weight management. Eli Lilly, the manufacturer, markets them separately with different pen colors and labeling.

Insurance coverage diverges significantly. Many commercial plans and Medicare Part D cover Mounjaro for type 2 diabetes while excluding Zepbound for obesity. Some patients with both type 2 diabetes and obesity may access tirzepatide more readily through a Mounjaro prescription. The SURMOUNT-2 trial established tirzepatide's efficacy in adults with type 2 diabetes and obesity [2], and clinicians managing both conditions may find a single agent covering both therapeutic goals.

The list price for both drugs is approximately $1,060 per month before insurance or manufacturer savings programs. Eli Lilly's savings card program for commercially insured patients may reduce out-of-pocket costs to $25 per fill for eligible patients. Medicare patients cannot access manufacturer savings cards under federal law.

Long-Term Weight Maintenance: What SURMOUNT-4 Tells Us

The weight regain data from SURMOUNT-4 are the most practical piece of information for patients deciding whether to start Zepbound. After 36 weeks of tirzepatide at 15 mg, participants re-randomized to placebo regained 14.8% of body weight over the subsequent 52 weeks, erasing roughly two-thirds of the weight they had lost [4]. Those who continued tirzepatide lost an additional 5.5% during the same period.

This mirrors findings from STEP-4 (semaglutide withdrawal trial) and reflects the biology of obesity: the hypothalamic and peripheral signals that drive weight regain persist after drug discontinuation. The American Association of Clinical Endocrinology's position, consistent with AACE/ACE guidelines, treats obesity as a chronic disease requiring ongoing management rather than a short-term intervention [9].

Patients and prescribers should approach Zepbound as a long-term commitment, not a fixed course. The SURMOUNT-4 withdrawal data suggest that 52 weeks of drug discontinuation returns approximately two-thirds of lost weight even after achieving maximum response at 15 mg [4].

Practical Considerations for Starting Zepbound

Baseline labs before starting Zepbound typically include fasting glucose, HbA1c, comprehensive metabolic panel, lipid panel, and thyroid function. A personal and family history screen for medullary thyroid carcinoma and MEN2 is required. Patients with a history of gallbladder disease should discuss cholelithiasis risk with their prescriber, as GLP-1 receptor agonists increase gallstone formation rate.

Dietary adjustments during the first eight weeks of treatment help minimize gastrointestinal side effects. Smaller meal portions, reduced fat content per meal, and adequate hydration (at least 2 liters daily) significantly reduce nausea severity in clinical practice. Alcohol tolerance may decrease on tirzepatide due to slowed gastric emptying and altered central reward signaling, though published RCT data on this specific effect are limited.

The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity endorses higher-efficacy agents including tirzepatide as preferred first-line pharmacotherapy in patients who meet prescribing criteria and have no contraindications.

Patients should bring their Zepbound autoinjector pen to room temperature for 30 minutes before injection. Pens should be stored refrigerated at 36°F to 46°F (2°C to 8°C) and discarded within 21 days if kept at room temperature.